The purpose of this research study is to give patient's with Chronic Myeloid Leukemia (CML) or Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) access to an experimental drug called ponatinib because other standard treatments haven’t worked or are no longer working for treatment of their leukemia. Ponatinib is being studied as a possible cancer treatment for CML and Ph+ ALL.